Antibodies against ILT2
AssigneeBiond Biologies Ltd.
InventorsIlana Mandel, Tsuri Peretz, Dana Haves Ziv, Ilana Goldshtein, Dror Alishekevitz, Anna Fridman-Dror, Motti Hakim, Avidor Shulman, Yair Sapir, Tehila Ben-Moshe
Life of this patent
Estimating the term…
Abstract
The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.
Claims14
A monoclonal antibody or an antigen-binding fragment thereof comprising three heavy chain CDRs (CDR-H) and three light chain CDRs (CDR-L), wherein:
- a. CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO:
- 13, CDR-H2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 14, CDR-H3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 15 wherein said X is selected from A, C and S, CDR-L1 comprises the amino acid sequence as set forth in SEQ ID NO:
- 16, CDR-L2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 17, and CDR-L3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 18;
- or
- b. CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO:
- 1, CDR-H2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 2, CDR-H3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 3, CDR-L1 comprises the amino acid sequence as set forth in SEQ ID NO:
- 4, CDR-L2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 5, and CDR-L3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 6;
- or
- c. CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO:
- 7, CDR-H2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 8, CDR-H3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 9, CDR-L1 comprises the amino acid sequence as set forth in SEQ ID NO:
- 10, CDR-L2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 11, and CDR-L3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 12.
A monoclonal antibody that comprises a heavy chain comprising SEQ ID NO:
- 28 and a light chain comprising SEQ ID NO:
- 24, wherein said antibody is an IgG4.
A monoclonal antibody or an antigen-binding fragment thereof comprising three heavy chain CDRs (CDR-H) and three light chain CDRs (CDR-L), wherein
- CDR-H1 comprises the amino acid sequence as set forth in SEQ ID NO:
- 13,
- CDR-H2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 14,
- CDR-H3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 25,
- CDR-L1 comprises the amino acid sequence as set forth in SEQ ID NO:
- 16,
- CDR-L2 comprises the amino acid sequence as set forth in SEQ ID NO:
- 17, and
- CDR-L3 comprises the amino acid sequence as set forth in SEQ ID NO:
- 18.
Dependencies are inferred from the claim text.